Edition:
United Kingdom

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

29.00USD
16 Sep 2019
Change (% chg)

$2.16 (+8.05%)
Prev Close
$26.84
Open
$26.99
Day's High
$29.16
Day's Low
$26.92
Volume
79,436
Avg. Vol
277,378
52-wk High
$29.16
52-wk Low
$1.94

Latest Key Developments (Source: Significant Developments)

Axsome Therapeutics Q2 Loss Per Share $0.41
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.41.Q2 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.AXSOME THERAPEUTICS - BOTH STRIDE-1 PHASE 3 TRIAL IN TRD & GEMINI PHASE 3 TRIAL IN MDD FOR AXS-05 ON TRACK FOR READOUT OF TOPLINE RESULTS IN 2H 2019.MOMENTUM PHASE 3 TRIAL OF AXS-07 IN MIGRAINE ON TRACK FOR READOUT OF TOPLINE RESULTS IN 2H 2019.CONCERT PHASE 2 TRIAL OF AXS-12 IN NARCOLEPSY ON TRACK FOR READOUT OF TOPLINE RESULTS IN 2H 2019.CASH RUNWAY EXTENDED INTO 4Q 2021.AT JUNE 30, 2019, AXSOME HAD $53.8 MILLION OF CASH COMPARED WITH $42.6 MILLION OF CASH AS OF MARCH 31, 2019.AXSOME THERAPEUTICS - BELIEVES ICASH AT JUNE 30, 2019 WILL BE SUFFICIENT TO FUND CO'S ANTICIPATED OPERATIONS INTO Q4 OF 2021.  Full Article

Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility
Monday, 29 Jul 2019 

July 29 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS AMENDS SILICON VALLEY BANK LOAN AGREEMENT INCREASING FINANCIAL FLEXIBILITY.AXSOME THERAPEUTICS INC - AMENDED ITS EXISTING $24 MILLION TERM LOAN FACILITY AGREEMENT LED BY SILICON VALLEY BANK.AXSOME THERAPEUTICS INC - AMENDMENT EXTENDS INTEREST-ONLY PAYMENT PERIOD.AXSOME THERAPEUTICS INC - AMENDMENT EXTENDS TIME FOR DRAWING DOWN ADDITIONAL FUNDING UNDER LOAN FACILITY.  Full Article

Axsome Therapeutics Announces Expedited Development And Pivotal Status For Axs-05 In The Treatment Of Major Depressive Disorder Based On FDA Breakthrough Therapy Meeting
Monday, 6 May 2019 

May 6 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES EXPEDITED DEVELOPMENT AND PIVOTAL STATUS FOR AXS-05 IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER BASED ON FDA BREAKTHROUGH THERAPY MEETING.AXSOME THERAPEUTICS INC - SCREENING TO CONTINUE TO BUILD REQUIRED NDA SAFETY DATABASE.AXSOME THERAPEUTICS INC - PREVIOUSLY COMPLETED ACTIVE-CONTROLLED ASCEND TRIAL IN MDD NOW CONSIDERED AS PIVOTAL.AXSOME THERAPEUTICS INC - TOPLINE RESULTS OF STRIDE-1 PHASE 3 TRIAL IN TRD AND PLANNED PLACEBO-CONTROLLED PHASE 3 TRIAL IN MDD EXPECTED IN 2H 2019.AXSOME THERAPEUTICS INC - INITIATION OF PLACEBO-CONTROLLED PHASE 3 TRIAL IN MDD ANTICIPATED IN 2Q 2019.AXSOME THERAPEUTICS INC - PREVIOUSLY COMPLETED ACTIVE-CONTROLLED ASCEND TRIAL IN MDD SUFFICIENT WITH ONGOING STRIDE-1 PHASE 3 TRIAL FOR NDA IN MDD.  Full Article

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation For AXS-05 For The Treatment Of Major Depressive Disorder
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR AXS-05 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER.  Full Article

Axsome Therapeutics's Major Depressive Disorder Treatment Meets Main Goal In Mid-stage Trial
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES AXS-05 ACHIEVES PRIMARY ENDPOINT IN PHASE 2 TRIAL IN MAJOR DEPRESSIVE DISORDER.AXSOME THERAPEUTICS - DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN MADRS SCORES COMPARED TO ACTIVE COMPARATOR (P<0.001 ON PRIMARY ENDPOINT).AXSOME THERAPEUTICS INC - AXS-05 MET PRESPECIFIED PRIMARY ENDPOINT.AXSOME THERAPEUTICS INC - AXS-05 WAS SAFE AND WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS.AXSOME THERAPEUTICS-AXS-05 WAS SUPERIOR TO BUPROPION ON MULTIPLE SECONDARY ENDPOINTS, WITH STATISTICALLY SIGNIFICANT EFFECTS DEMONSTRATED ON MOST.AXSOME THERAPEUTICS INC - TOPLINE RESULTS OF ONGOING PHASE 3 TRIAL OF AXS-05 IN TREATMENT RESISTANT DEPRESSION, ANTICIPATED LATER THIS QUARTER.AXSOME - RAPID IMPROVEMENT IN DEPRESSIVE SYMPTOMS SHOWING STATISTICALLY SIGNIFICANT SUPERIORITY OVER ACTIVE COMPARATOR WITHIN 1ST WEEK SEEN IN STUDY.AXSOME THERAPEUTICS INC - IMPROVEMENT WITH AXS-05 VERSUS ACTIVE COMPARATOR SEEN ON MULTIPLE SECONDARY ENDPOINTS SEEN IN STUDY.  Full Article

Axsome Therapeutics Qtrly Loss Per Share $0.31
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.FINAL PHASE 3 RESULTS OF AXS-05 IN TREATMENT RESISTANT DEPRESSION NOW ANTICIPATED IN 1Q 2019.FINAL PHASE 2 RESULTS OF AXS-05 IN MAJOR DEPRESSIVE DISORDER ANTICIPATED AROUND YEAR-END 2018.PHASE 2/3 INTERIM ANALYSIS RESULTS OF AXS-05 IN ALZHEIMER'S DISEASE AGITATION ANTICIPATED IN 4Q 2018.PHASE 3 TRIAL OF AXS-07 IN ACUTE MIGRAINE ANTICIPATED TO START IN 4Q 2018 TO 1Q 2019.PHASE 2 TRIAL OF AXS-12 IN NARCOLEPSY ANTICIPATED TO START IN 4Q 2018.QTRLY LOSS PER SHARE $0.31.Q3 EARNINGS PER SHARE VIEW $-0.29 -- THOMSON REUTERS I/B/E/S.  Full Article

Axsome Therapeutics Initiates Phase 2 Trial Of Axs-05 In Major Depressive Disorder
Tuesday, 5 Jun 2018 

June 5 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS INITIATES PHASE 2 TRIAL OF AXS-05 IN MAJOR DEPRESSIVE DISORDER.AXSOME THERAPEUTICS INC - FIRST PATIENT ENROLLED IN ASCEND STUDY.AXSOME THERAPEUTICS INC - TOPLINE RESULTS FROM ASCEND TRIAL ARE EXPECTED IN SECOND HALF OF 2018.  Full Article

Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19
Tuesday, 8 May 2018 

May 8 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.19.AT MARCH 31, 2018, AXSOME HAD $26.6 MILLION OF CASH COMPARED TO $34.0 MILLION OF CASH AT DECEMBER 31, 2017.BELIEVES CURRENT CASH WILL BE SUFFICIENT TO FUND OPERATIONS, BASED ON CURRENT OPERATING PLANS, INTO Q3 OF 2019.  Full Article

Axsome Therapeutics Says Independent Committee Recommends Continuation Of Depression Trial
Thursday, 26 Apr 2018 

April 26 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS ANNOUNCES POSITIVE OUTCOME OF INTERIM ANALYSIS OF STRIDE-1 PHASE 3 TRIAL OF AXS-05 IN TREATMENT RESISTANT DEPRESSION.AXSOME THERAPEUTICS INC - SECOND INTERIM ANALYSIS ANTICIPATED SECOND HALF OF 2018 FOR EFFICACY.AXSOME THERAPEUTICS INC - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS TRIAL CONTINUATION.AXSOME THERAPEUTICS INC - IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION FROM STUDY AND INDICATED AXS-05 APPEARED SAFE AND WELL-TOLERATED.  Full Article

Axsome Therapeutics Reports Q4 Loss Per Share $0.31
Wednesday, 7 Mar 2018 

March 7 (Reuters) - Axsome Therapeutics Inc ::AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.31.AXSOME THERAPEUTICS - BELIEVES CASH AT DEC 31, 2017 TO BE SUFFICIENT TO FUND ANTICIPATED OPERATIONS INTO Q3 2019.AT DECEMBER 31, 2017, AXSOME HAD $34.0 MILLION OF CASH COMPARED TO $36.6 MILLION OF CASH AT DECEMBER 31, 2016.  Full Article